First human tests for potential hemophilia treatment
NCT ID NCT05493631
Summary
This early-stage study tested the safety of a new experimental drug called MG1113 for people with severe hemophilia. Fifteen adult male patients received weekly injections for eight weeks while researchers carefully monitored for side effects. The main goal was to understand how safe the drug is and how the body processes it before testing whether it helps control bleeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GC Biopharma Corp.
Yongin-si, Gyeonggi-do, 16924, South Korea
Conditions
Explore the condition pages connected to this study.